Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
Extending an HPV vaccination programme to include boys aged 12–14 years could help reduce the incidence of these infections
A growing body of evidence has identified Notch mutations as a potential target in adenoid cystic carcinoma (ACC), a rare type of salivary gland carcinoma
Two post-hoc analyses of KEYNOTE studies presented at ESMO 2019
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.